PRNewsWire
21 Oct 2026, 18:40 UTC · 1h ago
Impact · against what's priced in
The article serves as a legal notice for an existing securities fraud class action following a known FDA failure. Since the 39.1% price drop and the second CRL occurred in June 2026, the current valuation already reflects the regulatory setback and the ensuing litigation risk.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
The FDA issued a second Complete Response Letter (CRL) on June 30, 2026, for oxylanthanum carbonate due to recurring third-party manufacturing deficiencies.
Priced indisclosure occurred on June 30, 2026
More negative than 99% of claims this week
The stock price dropped 39.1%, or $3.01, to close at $4.69 per share following the FDA news on June 30, 2026.
Priced in
Continue reading
5 related stories
The article confirms a lead plaintiff deadline of November 2, 2026, for a lawsuit stemming from a June 30 CRL and a 39.1% stock drop. While the legal process is advancing, the underlying catalyst—the manufacturing failure and price collapse—has already occurred.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
So whatThe steep decline in market cap significantly reduces the company's ability to raise equity capital without massive dilution.
More negative than 90% of claims this week
Unicycive Therapeutics is facing a securities fraud class action lawsuit alleging misleading statements regarding its manufacturing oversight between December 2025 and June 2026.
Priced infiled on September 3, 2026
So whatLegal liabilities and potential settlement costs will create a drag on cash reserves in FY2027.
More negative than 75% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is facing a class action lawsuit for securities fraud following a 39.1% stock drop and a second FDA Complete Response Letter.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1h ago
+1.8%
Price is moving against the score
$3.87 vs $3.80 close before publication (Oct 20) · not market-adjusted
UNCY chart →
